8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 27, 2026·SEC
XOMA Royalty Corp.(XOMA)Earnings, Financials & Key Ratios
XOMA•NASDAQ
$43.89
30.1× P/E·Price updated Jul 7, 2026
AboutXOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Show more
- Revenue$52M+83.1%
- EBITDA$14M+136.1%
- Net Income$32M+329.4%
- EPS (Diluted)1.46+188.5%
- Gross Margin94.3%-5.0%
- EBITDA Margin27.53%+119.7%
- Operating Margin21.83%+115.6%
- Net Margin60.81%+225.3%
- ROE34.12%+310.6%
XOMA Price & Volume
XOMA Royalty Corp. (XOMA) stock price & volume — 10-year historical chart
Loading chart...
Erratic Milestone Revenue Masks Portfolio Scaling Potential
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Binary Milestone Revenue Volatility
Key Thesis Takeaways
- XOMA is transitioning into a diversified royalty holding company, yet its financial performance remains heavily tethered to the unpredictable timing of milestone payments across its 70-asset portfolio.
- While the company maintains a robust liquidity position with $94.5M in cash, investors should monitor the persistent drag of SG&A expenses, which reached $11.9M in 2026Q1, against the volatility of its core royalty income.
- The long-term thesis depends on the company's ability to convert its intangible asset base into consistent, non-dilutive cash flows while managing the inherent risks of binary clinical outcomes.
Verdict Logic
while the company holds a healthy current ratio of 3.59, the high P/FCF multiple of 184.12 suggests that the market is pricing in significant future growth that remains vulnerable to lumpy, milestone-dependent revenue streams.
XOMA Growth Metrics
XOMA Royalty Corp. (XOMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.61%
5 Years12.16%
3 Years105.3%
TTM-3.33%
Profit CAGR
10 Years-
5 Years18.98%
3 Years-
TTM1202.1%
EPS CAGR
10 Years-
5 Years13.36%
3 Years-
TTM317.39%
Return on Capital
10 Years-22.21%
5 Years-7.44%
3 Years-12.74%
Last Year5.24%
XOMA Recent Earnings
XOMA Royalty Corp. (XOMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.17-10.5%
$0.19
Rev
$14M+0.3%
$14M
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.12+192.3%
$0.13
Rev
$14M+24.5%
$11M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.35-1650.0%
$0.02
Rev
$9M-16.0%
$11M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.48+500.0%
$0.12
Rev
$13M+32.3%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.17vs $0.19-10.5% | $14Mvs $14M+0.3% |
| Q2 2026 | Mar 18, 2026 | $0.12vs $0.13+192.3% | $14Mvs $11M+24.5% |
| Q4 2025 | Nov 12, 2025 | $0.35vs $0.02-1650.0% | $9Mvs $11M-16.0% |
| Q3 2025 | Aug 13, 2025 | $0.48vs $0.12+500.0% | $13Mvs $10M+32.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for XOMA Royalty Corp. (XOMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $43.89 | $550.42M | 30.06 | 83.06% | 60.81% | 34.12% | 0.69% | |
| $57.80 | $24.76B | 32.11 | 5.06% | 33.9% | 8.54% | — | |
| $4.38 | $303.37M | -1.39 | 105.77% | -344.95% | -35.74% | — | |
| $107.17 | $5.17B | 16.89 | 5.91% | 32.63% | 49.18% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — |
Compare XOMA vs Peers
XOMA Royalty Corp. (XOMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XOMA SEC Filings & Documents
XOMA Royalty Corp. (XOMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XOMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XOMA Frequently Asked Questions
XOMA Royalty Corp. (XOMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is XOMA Royalty Corp.'s revenue?
XOMA Royalty Corp. (XOMA) reported $36.2M in revenue for fiscal year 2025. This represents a 906% increase from $3.6M in 1996.
How fast is XOMA Royalty Corp. growing?
XOMA Royalty Corp. (XOMA) grew revenue by 83.1% over the past year. This is strong growth.
Is XOMA profitable?
Yes, XOMA Royalty Corp. (XOMA) is profitable, generating $31.5M in net income for fiscal year 2025 (60.8% net margin).
Dividend & Returns
Does XOMA pay dividends?
Yes, XOMA Royalty Corp. (XOMA) pays a dividend with a yield of 0.69%. This makes it attractive for income-focused investors.
What is XOMA's return on equity?
XOMA Royalty Corp. (XOMA) has a return on equity (ROE) of 34.1%. This is excellent, indicating efficient use of shareholder capital.
What is XOMA Royalty Corp.'s free cash flow?
XOMA Royalty Corp. (XOMA) generated $6.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.